Neurocentrum Bydgoszcz Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The research at Neurocentrum Bydgoszcz focuses on Generalized Myasthenia Gravis, assessing a novel antibody therapy to improve patients' daily functioning and overall disease control.
- Therapeutic antibody development
- Patient‑reported outcome measures
- Seropositive disease mechanisms
The site’s investigators are evaluating the effectiveness of the treatment while monitoring safety, aiming to provide new options for individuals living with this autoimmune neuromuscular disorder.
Nervous System Diseases
Ongoing studies target multiple sclerosis, examining the long‑term safety and tolerability of a promising oral agent to support disease stability in both relapsing and progressive forms.
- Disease‑modifying therapy assessment
- Progression biomarker evaluation
- Quality of life monitoring
Researchers aim to deepen understanding of treatment impact on neuro‑inflammation, helping to shape future care strategies for patients across the disease spectrum.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 77 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 77 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG13trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neurocentrum Bydgoszcz Sp. z o.o.
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 77 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 9 | Unknown | 2018-07-25 | 2026-06-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.